Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Molnupiravir
MK-4482 · 2 trials · 1 indication
Cmax of N-hydroxycytidine (NHC) after a single oral dose of MK-4482 in period 1.
Tmax of NHC following single oral dose of MK-4482 in period 1.
T1/2 is defined as the time required for the concentration or amount of NHC in the body to be reduced by one-half after a single oral dose of MK-4482 in period 1.
CL/F of NHC from plasma after single oral dose of MK-4482 in period 1.
Vz/F of NHC during terminal phase after single oral dose of MK-4482 in period 1.
This is a measure of the average amount of NHC in the plasma over a period of 12 hours after single oral dose of MK-4482 in period 1.
AUC0-last of NHC following a single oral dose of MK-4482 in period 1.
AUC0-inf of NHC after single oral dose of MK-4482 in period 1.
Cmax of NHC after multiple oral doses of MK-4482 in period 2.
Tmax of NHC following multiple oral doses of MK-4482 in period 2.
T1/2 is defined as the time required for the concentration or amount of NHC in the body to be reduced by one-half after multiple oral doses of MK-4482 in period 2.
CLss/F of plasma NHC following multiple doses of MK-4482 in period 2.
Vz/F of NHC during terminal phase after multiple doses of MK-4482 in period 2.
This is a measure of the average amount of NHC in the plasma over a period of 12 hours after multiple oral doses of MK-4482 in period 2.
Ctrough of NHC that occurred following multiple doses of MK-4482 in period 2.
The maximum concentration at steady state following multiple doses of MK-4482 in period 2 divided by the maximum concentration following the initial dosing in Period 1.
The AUC0-12hr at steady state following multiple doses of MK-4482 in period 2 divided by the AUC0-12hr following the initial dosing in Period 1.
AUC0-inf of NHC in plasma will be determined.
AUC0-last of NHC in plasma will be determined.
AUC0-12 of NHC in plasma will be determined.
Cmax of NHC in plasma will be determined.
Tmax of NHC in plasma will be determined.
t1/2 of NHC in plasma will be determined.
CL/F of NHC in plasma will be determined.
Vz/F of NHC in plasma will be determined.
| Arm | Type | Description |
|---|---|---|
| MK-4482 | EXPERIMENTAL | Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses. |
| Molnupiravir Treatment A | EXPERIMENTAL | Participants receive molnupiravir reference capsule. |
| Molnupiravir Treatment B | EXPERIMENTAL | Participants receive molnupiravir Formulation 1. |
| Molnupiravir Treatment C | EXPERIMENTAL | Participants receive molnupiravir Formulation 1 after a high-fat meal. |
| Molnupiravir Treatment D | EXPERIMENTAL | Participants receive molnupiravir Formulation 2. |
| Name | Type | Description |
|---|---|---|
| MK-4482 | DRUG | Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses. |
| Molnupiravir | DRUG | Oral Administration. |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: \- Has a Body Mass Index (BMI) of 19 to 24 weight (kg)/height (m)2, inclusive, and body weight of ≥ 50 kg at the screening visit. Exclusion Criteria: The main exclusion criteria include but are not limi...
MK-4482, also known as Molnupiravir, is an investigational small molecule being studied for Coronavirus Disease (COVID-19), Renal Impairment, Respiratory Syncytial Virus, Hepatic Impairment, Influenza Infection, and in Healthy participants. It is in Phase 1 clinical development.
MK-4482, also known as Molnupiravir, is a small molecule antiviral. Its specific molecular target has not been disclosed in the available clinical trial information.
MK-4482, also known as Molnupiravir, is being developed by Merck & Company, Inc. (ticker: MRK).
MK-4482, also known as Molnupiravir, is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
MK-4482, also known as Molnupiravir, has been studied in several Phase 1 trials, including NCT05386758 in participants with severe renal impairment, NCT05818124 in healthy participants inoculated with experimental influenza virus, NCT06615869 comparing tablet and capsule formulations, and NCT06816030 in Chinese healthy male participants.
Yes, MK-4482 is also known as Molnupiravir. Both names refer to the same investigational drug being developed by Merck & Company, Inc.